» Articles » PMID: 33223139

Clear Cell Papillary Renal Cell Carcinoma: an Update After 15 Years

Overview
Journal Pathology
Specialty Pathology
Date 2020 Nov 23
PMID 33223139
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Fifteen years since the first recognition of clear cell papillary renal cell carcinoma, this distinct renal tumour type is now well accepted as a distinct entity in major classification schemes. It occurs both with and without end-stage renal disease and may be multifocal or bilateral in both scenarios. Recognisable morphological features include clear cells lining branching glands and variable papillary formations with nuclear alignment. Most tumours are small (pT1a) and nucleolar grade 1-2. Immunohistochemistry consistently shows positivity for carbonic anhydrase IX and cytokeratin 7, and often high molecular weight cytokeratin or GATA3, the latter suggesting distal nephron phenotype. Labeling for AMACR and CD10 is consistently negative or minimal. Despite a resemblance to clear cell renal cell carcinoma, molecular alterations of VHL and chromosome 3p are typically lacking, with debatable rare exceptions. Potential mimics include clear cell renal cell carcinoma (with branching architecture or nuclear alignment), papillary renal cell carcinoma with clear cytoplasm, or rarely MITF family translocation renal cell carcinoma. Clinical behaviour is highly favourable with rare, debatable reports of aggressive behaviour. Combined with striking similarity to several extrarenal benign neoplasms, it would be reasonable to reclassify this entity as a benign or low malignant potential neoplasm. Using the nomenclature of the extrarenal counterparts, clear cell papillary (cyst)adenoma is proposed.

Citing Articles

Diagnostic Biomarkers in Renal Cell Tumors According to the Latest WHO Classification: A Focus on Selected New Entities.

Sanguedolce F, Mazzucchelli R, Falagario U, Cormio A, Zanelli M, Palicelli A Cancers (Basel). 2024; 16(10).

PMID: 38791935 PMC: 11120103. DOI: 10.3390/cancers16101856.


AURKA promotes renal cell carcinoma progression via regulation of CCNB1 transcription.

Wen J, Wang X, Yang G, Zheng J Heliyon. 2024; 10(8):e27959.

PMID: 38655290 PMC: 11035947. DOI: 10.1016/j.heliyon.2024.e27959.


Identification of cuproptosis-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma.

He Y, Zhang H, Li J, Zhou H, Wang F, Zhang G J Genet Eng Biotechnol. 2024; 22(1):100338.

PMID: 38494257 PMC: 10860879. DOI: 10.1016/j.jgeb.2023.100338.


Exploring the anticancer potential of hydrogen sulfide and BAY‑876 on clear cell renal cell carcinoma cells: Uncovering novel mutations in VHL and KDR genes among ccRCC patients.

Hamadamin P, Maulood K Mol Clin Oncol. 2024; 20(3):21.

PMID: 38332991 PMC: 10851183. DOI: 10.3892/mco.2024.2719.


Clear cell renal cell carcinoma with mutation: a report of two cases.

Lee J, Thuzar M, DiPoto-Brahmbhatt A, Chaudoir C, Tanner A, Fazili T Am J Clin Exp Urol. 2023; 11(5):429-434.

PMID: 37941648 PMC: 10628621.